ASH 2025
Dec 6 - 9, 2025 | Orlando, FL
The agents listed below are currently under investigation. Their safety and efficacy have not been established.
Poster
ARV-393, a PROTAC BCL6 Degrader, Combined With the CD20×CD3 Bispecific Glofitamab in a Preclinical Model of HGBCLA Van Acker et al.